

Independent Auditors' Report

The Board of Directors

Strides Pharma Science Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Strides Pharma Inc and its Subsidiary ("the Company"), which comprise the consolidated balance sheet as at 31 March 2025, the consolidated statement of income, changes in stockholder's equity and cash flows for the year then ended, and notes, including significant accounting policies and other explanatory information.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at 31 March 2025, and its consolidated results of operations and its consolidated cash flows for the year then ended in accordance with U.S generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We are independent of the Company in accordance with International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the consolidated financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Board of Directors for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S generally accepted accounting principles, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Registered Office:

Board of Directors of the Company is responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

B S R & Co. LLP

We communicate with Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

for **B S R & Co. LLP**

Chartered Accountants

ICAI Firm Registration Number: 101248W/W-100022

Sagar Lulla

Partner

Membership No. 137645

UDIN: 25137645BMOHKR9624

Place: Bengaluru

Date: 28 June 2025





STRIDES PHARMA INC.
CONSOLIDATED BALANCE SHEET
AS AT MARCH 31, 2025 AND MARCH 31, 2024

(All amounts in \$, except share and per share data)

	Note	31-Mar-25	31-Mar-24
I Assets			
Current assets			
(a) Cash and cash equivalents		4,697,048	677,965
(b) Accounts receivable, net	2	61,300,914	42,049,875
(c) Inventories	3	72,913,110	54,717,102
(d) Other current assets	4	20,547,411	13,294,366
Total current assets		159,458,483	110,739,308
(a) Investments	5	34,157,607	34,161,122
(b) Property, plant and equipment, net	6	28,519,350	27,327,032
(c) Goodwill	7	26,174,783	26,174,783
(d) Operating lease right-of-use assets	19	3,347,841	4,435,053
(e) Other intangible assets, net	7	13,442,165	11,245,223
(f) Deferred tax assets, net	18	5,213,534	4,231,583
(g) Other non-current assets	8	3,939,135	1,139,752
Total assets		274,252,898	219,453,856
II Liabilities and equity			
Current liabilities			
(a) Accounts payable		88,224,998	44,199,367
(b) Other current liabilities			
(i) Accrued payables	9	9,975,214	5,903,476
(ii) Accrued taxes		2,749,388	751,732
(iii) Capital vendors		599,862	-
(c) Operating lease liabilities	19	1,126,960	1,223,293
(d) Short-term debt	10	-	8,000,000
(e) Current maturities of long-term debt	10	1,278,642	1,010,936
(f) Contingent consideration payable	26	-	678,341
(g) Provision for sales returns		5,188,733	4,871,667
Total current liabilities		109,143,797	66,638,812
(a) Operating lease liabilities	19	2,401,758	3,253,733
(b) Long-term debt	10	50,397,080	45,551,932
(c) Provision for sales returns		6,280,000	4,413,709
(d) Payable to related parties	11	3,136,618	3,136,618
Total liabilities		171,359,253	122,994,804
Commitments and contingencies	24		
Stockholders' equity:			
Common stock, \$10 par value per share	12	183,830	183,830
Authorized 100,000 shares; issued and outstanding: 18,383 shares as at March 31, 2025 (18,383 shares as at March 31, 2024)			
Additional paid-in capital		66,512,694	66,512,694
Retained earnings		36,197,121	29,762,528
Total equity		102,893,645	96,459,052
Total liabilities and stockholders' equity		274,252,898	219,453,856

See accompanying notes to the consolidated financial statements.







STRIDES PHARMA INC.
CONSOLIDATED STATEMENT OF INCOME
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(All amounts in \$, except share and per share data)

	Note	For the year ended	
		31-Mar-25	31-Mar-24
Revenue from operations, net	13	266,237,214	213,254,416
<i>Operating expenses</i>			
(a) Cost of revenues	14	232,069,870	178,405,354
(b) Selling, general and administrative expenses	15	45,498,075	43,618,590
(c) Depreciation and amortization	6,7	3,905,193	3,464,609
(d) Other operating income	16	(28,824,939)	(24,790,509)
Total operating expenses		252,648,199	200,698,044
Income from operations		13,589,015	12,556,372
Unwinding impact/ Fair Valuation of contingent consideration payable		(678,341)	(640,709)
Other (income) / expense	17	(26,132)	(5,603)
Interest expense		6,068,750	6,087,508
Income from operations before income taxes		8,224,738	7,115,176
Income tax expense	18	1,790,145	1,415,352
Net income		6,434,593	5,699,824

See accompanying notes to the consolidated financial statements.







STRIDES PHARMA INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEARS ENDED MARCH 31, 2025 AND MARCH 31, 2024

(All amounts in \$, except share and per share data)

	31-Mar-25	31-Mar-24
A Cash flows from operating activities:		
Net income	6,434,593	5,699,824
Adjustments to reconcile net profit to net cash (used in) / flow from operating activities:		
Depreciation and amortisation	3,905,193	3,464,609
Income taxes (Including deferred tax)	1,790,145	1,415,352
Fair value loss on investments	3,515	12,581
Unwinding impact/ Fair Valuation of contingent consideration payable	(678,341)	(640,709)
Changes in net operating assets and liabilities:		
Accounts receivable, net	(19,441,124)	32,920,159
Inventories	(15,487,828)	8,773,454
Prepaid expenses, other current assets and security deposits	(5,452,299)	23,586,112
Accounts payables	43,288,736	(45,984,079)
Other current liabilities, operating lease liabilities and other liabilities	1,214,928	8,388
Income taxes (net)	(2,234,068)	(1,623,029)
Net cash flow from in operating activities	13,343,450	27,632,662
B Cash flows from investing activities:		
Purchase of property, plant and equipment	(5,787,572)	(2,347,240)
Purchase of other intangible assets	(649,649)	-
Net cash used in investing activities	(6,437,221)	(2,347,240)
C Cash flows from financing activities:		
Proceeds from long term debt	6,123,790	-
Repayment of long term debt	(1,010,936)	(25,577,680)
Repayment of short term debt	(8,000,000)	-
Net cash used in financing activities	(2,887,146)	(25,577,680)
Cash and cash equivalents and restricted cash:		
Net increase / (decrease) in cash and cash equivalents	4,019,083	(292,258)
Balance at the beginning of the year	677,965	970,223
Balance at the end of the year	4,697,048	677,965
Supplemental cash flow information:		
Cash paid for interest	6,143,685	6,167,952
Reconciliation of cash and cash equivalents in the consolidated balance sheets:		
Cash and cash equivalents	4,697,048	677,965
Total cash and cash equivalents shown in the consolidated statement of cash flows	4,697,048	677,965

See accompanying notes to the consolidated financial statements.







STRIDES PHARMA INC.
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(All amounts in \$, except share and per share data)

Particulars	Common stock		Additional paid-in capital	Retained earnings	Total equity
	Shares	Amount			
Balance as at April 1, 2023	18,383	183,830	66,512,694	24,062,704	90,759,228
Net income for the year	-	-	-	5,699,824	5,699,824
Balance as at March 31, 2024	18,383	183,830	66,512,694	29,762,528	96,459,052
Net income for the year	-	-	-	6,434,593	6,434,593
Balance as at March 31, 2025	18,383	183,830	66,512,694	36,197,121	102,893,645

See accompanying notes to the consolidated financial statements.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

1 Summary of significant accounting policies

1.1 Company overview and description of business:

Strides Pharma, Inc. (the "Company"), having headquarters in Bridgewater, New Jersey, was incorporated on June 26, 2013 in the State of New Jersey. The Company is in the business of manufacturing, marketing, selling and distributing generic prescription drugs in United States of America.

Strides Pharma Science Limited (the "Ultimate Parent") owns 100% of Strides Arcolab International Limited, UK (the "parent"), which owns 100% of the Company. The ultimate parent company and all its subsidiaries are herein referred to as Strides Group. The Ultimate Parent company is incorporated in India and is listed on the National Stock Exchange of India and the Bombay Stock Exchange of India.

The Company owns 9.64% of Strides Pharma Global (UK) Limited (a subsidiary of parent company). The Ultimate Parent also owns 100% of Strides Pharma Asia Pte Limited, Singapore which owns 100% of Strides Pharma Global Pte Limited, Singapore ("SPG").

The Company is dependent upon the Ultimate Parent, SPG & its facility in Chestnut Ridge for manufacturing and supply of products, research and development efforts, and for the continued use of (or access to) drug formulations and intellectual property that are essential in Rx products and related operations.

1.2 Basis of preparation and principles of financial statements

The accompanying consolidated financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles ("US GAAP").

1.3 Use of estimates

Preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Appropriate changes in estimates are made as and when management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the consolidated financial statements in the period in which changes are made and if material, their effects are disclosed in the notes to the consolidated financial statements. Significant estimates include amounts deducted from revenue for the projected chargebacks, sales returns, rebates and medicaid, the valuation of receivables, goodwill impairment, investments and intangible assets. Actual results could differ from those estimates.

1.4 Principles of consolidation

The accompanying consolidated financial statements include the accounts of Strides Pharma, Inc. and its fully owned subsidiary, Vensus Pharmaceuticals Inc. (collectively, the Group). All intercompany balances and transactions have been eliminated in consolidation. The Group has no involvement with variable interest entities.


1.5 Business combination

The application of business combination accounting requires the use of significant estimates and assumptions. The Group accounts for business combinations using the acquisition method of accounting, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. The measurement of purchase price, including future contingent consideration, if any, and its allocation, requires significant estimates in determining the fair values of assets acquired and liabilities assumed, including with respect to intangible assets and deferred and contingent consideration. Significant estimates and assumptions made include, but are not limited to, the timing and amount of future revenue and cash flows based on, among other things, anticipated growth rates, customer attrition rates, and the discount rate reflecting the risk inherent in future cash flows.

The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

1.6 Cash and cash equivalents

Cash equivalents consist of highly liquid investments with an initial maturity of three months or less. The carrying value of cash and cash equivalents approximates fair value because of the short maturities of those financial instruments. Cash balances in bank accounts are insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$ 250,000 (previous year – \$ 250,000) for each insured bank for each account per depositor.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

1 Summary of significant accounting policies (continued)

1.7 Accounts receivable and allowance for doubtful accounts

The Group extends credit to customers based upon management's assessment of their creditworthiness. To avoid risk with accounts receivable, the Group routinely analyzes the financial strength of customers.

In the normal course of business, the Group provides credit to its customers, performs credit evaluations of these customers, and maintains reserves for potential credit losses. The Group follows the specific identification method for recognizing provision for doubtful debts. Management analyzes composition of the accounts receivable aging, payment history, historical bad debts, current economic trends, and customer credit worthiness of each accounts receivable when evaluating the adequacy of the provision for doubtful accounts. Provision for doubtful debt is included in selling, general and administrative expenses in the consolidated statement of income.

The Group derecognises accounts receivable which are factored without recourse to the bank where the group has transferred substantially all risk and rewards of ownership over such receivables.

1.8 Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation, and accumulated impairment losses, if any.

Cost of items of property, plant and equipment comprise cost of purchase and other costs necessarily incurred to bring it to the condition and location necessary for its intended use. Such properties are classified to the appropriate categories of property, plant and equipment when completed and ready for intended use. Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the group. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

The Group depreciates property, plant and equipment over the estimated useful life using the straight-line method. Maintenance and repair costs are charged to expense as incurred. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is reported in consolidated statement of Income.

The estimated useful lives of the assets are as follows:

Buildings	20-30 years
Computers	3 years
Office equipment	5 years
Furniture and fixtures	10 years
Plant and machinery	4-15 years

Land is not depreciated.

Capital work-in-progress are those which are not ready for intended use and are carried at cost less impairment loss, if any.

1.9 Intangible assets

The Intangible assets including those acquired by the Group are initially measured at cost. Such intangible assets are subsequently measured at cost less accumulated amortisation and any accumulated impairment losses. Intangible assets with finite lives are amortized over their respective estimated useful lives to their estimated residual values.

Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses (if any). However, the group does not have any intangible assets with indefinite useful life.

The estimated useful lives of the assets are as follows:

Registrations and brands	10-15 years
Software licenses	5 years

Expenditure on research and development activities is recognised as an expense in the period in which it is incurred.



1 Summary of significant accounting policies (continued)

1.10 Impairment of long lived assets

The Group reviews the carrying amounts of long-lived assets, other than goodwill and intangible assets not subject to amortization, for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating recoverability, the Group's assets and liabilities at the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows of other assets and liabilities. The Group then compares the carrying amounts of the assets or asset groups with the related estimated undiscounted future cash flows. In the event impairment exists, an impairment charge is recorded as the amount by which the carrying amount of the asset or asset group exceeds the fair value.

1.11 Goodwill

Goodwill is the excess of the purchase price over the fair value of acquired assets and liabilities in a business combination. The Group accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other (“ASC 350”). ASC 350 requires that goodwill and other intangibles with indefinite lives should be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value.

Effective January 01, 2017, the Group prospectively adopted the provisions of Accounting Standards Update 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). ASU 2017-04 eliminates the second step of the goodwill impairment test. Therefore, for goodwill impairment tests occurring after January 01, 2017, if the carrying value of a reporting unit exceeds its fair value, the Group will measure any goodwill impairment losses as the amount by which the carrying amount of a reporting unit exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit.

Based on the assessment, the Group has determined that the fair values of all of the reporting units are likely to be higher than their respective carrying amounts as of March 31, 2025.

1.12 Investments

a) Investments at cost

Investments in preferred stock of related parties are carried at cost. Acquisition related expenditure is expensed in the year of incurring the same.

The Group has elected to apply the measurement alternative to equity securities without readily determinable fair values, i.e., investments in related parties. As such, non-marketable equity securities of the Group are measured at cost, less any impairment, and are adjusted for changes in fair value resulting from observable transactions for identical or similar investments of the same issuer. Gains and losses on non-marketable equity securities are recognized in consolidated statement of Income.

b) Investments at fair value


Equity interests, other than investments in related parties, with readily determinable fair values are carried at fair value with changes in value recorded in the consolidated statement of Income.

1.13 Inventories

Inventories are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges. Work-in-progress and finished goods include appropriate proportion of overheads. Cost is determined as follows:

- Raw materials, packing materials, stores and spares: weighted average basis
- Work-in progress: at material cost and an appropriate share of production overheads
- Finished goods: material cost and an appropriate share of production overheads, wherever applicable
- Stock-in trade: weighted average basis

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

1 Summary of significant accounting policies (continued)

1.14 Revenue recognition

The Group recognises revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. A 5-step approach is used to recognise revenue as below:

- Step 1: Identify the contract(s) with a customer
- Step 2: Identify the performance obligation in contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation

The Group recognizes revenue when it satisfies performance obligations under the terms of its contracts, and control of its products and services is transferred to its customers in an amount that reflects the consideration the Group expects to receive from its customers in exchange for those products and services.

The timing of transfer of control varies depending on the individual terms of sale, usually in case of domestic, such transfer occurs when the product is delivered to the customer.

1.14.1 Sale of Goods:

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration primarily related to rebates and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. The Group estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Group's best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period.

The significant adjustments to revenue are explained below:

- a. A chargeback claim represents an amount payable in the future to Wholesaler for the difference between the invoice price (Wholesaler Acquisition Cost) and the negotiated contract price that the wholesaler pays for the product. Provision for chargeback is calculated on the basis of historical experience and specific terms in the individual agreements.
- b. Provision for rebates and fees is calculated based on historical experience and specific terms in the individual agreements.
- c. Provision for sales returns are estimated on the basis of historical experience, market conditions and specific contractual terms and provided for in the year of sale as reduction from revenue. The methodology and assumptions used to estimate returns are monitored and adjusted regularly in line with contractual and legal obligations, trade practices, historical trends, past experience and projected market conditions.
- d. Group products covered by the Medicaid program are required to pay rebate to each state a percentage of their average manufacturer's price ('AMP') for the products dispensed. Medicaid rebates are estimated based on historical trends of rebates paid.
- e. Shelf stock adjustments are credits issued to customers to reflect decrease in selling price of the products. These credits are customary in the industry and are intended to reduce the customers' inventory cost to reflect current market prices. The decision to grant a shelf stock adjustment to a customer following a price decrease is made at the Group's discretion.

1.14.2 Capacity Reservation fees

Capacity Reservation fees is recognised as an income over the period as per the terms of the contracts



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

1 Summary of significant accounting policies (continued)

1.15 Selling, general and administrative expenses

Selling, general and administrative costs are expenses as incurred. These expenses primarily includes advertisement and marketing cost, personnel cost, warehousing and freight outwards, legal and professional fees.

1.16 Cost of revenues

Cost of revenue primarily includes Purchase cost of finished goods, freight inward, packing cost, cost of manufacturing (including the cost of manufacturing personnel)

1.17 Employee benefits

Defined contribution plans

Employees of the Group participate in an employee retirement savings plan (the "401K Plan") under Section 401(K) of the United States Internal Revenue Code. The 401K Plan allow employees to defer a portion of their annual earnings on a pre-tax basis through voluntary contributions to the 401K Plan.

For the year ended March 31, 2025, the Group recorded contributions of \$649,080 (March 31, 2024: \$577,904) towards 401K Plan. The Group has additionally contributed towards Social Security and Medicare amounting to \$1,503,635 million for the year ended March 31, 2025 (March 31, 2024: \$1,394,305).

1.18 Government grant

Government grant is recognized only when there is a reasonable assurance that:

- (a) the entity will comply with any conditions attached to the grant, and
- (b) the grant will be received.


Accordingly, the Group will recognize grants as a reduction of the expense to which it relates in the consolidated statements of income when all performance obligations have been satisfied and forgiveness is reasonably assured. However, the group does not have any such government grant.

1.19 Commitments and contingencies

Liabilities for loss contingencies arising from claims, assessments, litigations, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. Contingent liabilities are not recognized but are disclosed in the notes as referred in Note 24. Contingent assets are neither recognized nor disclosed in the consolidated financial statements.

1.20 Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Group recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Group records interest related to unrecognized tax benefits in interest expense and penalties in selling, general, and administrative expenses.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

1 Summary of significant accounting policies (continued)

1.21 Operating leases

The Group elected to early adopt ASU 2016-02 (Topic 842 or Lease) on April 1, 2019 using a modified retrospective transition approach as permitted by the amendments in ASU 2018-11. As a result, the Company was not required to adjust its comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption.

The Group determines whether an arrangement is or contains a lease at contract inception. All of the Group's leases are classified as operating leases, which are included in operating lease right-of-use assets (ROU) and operating lease liabilities in the consolidated balance sheet.

Topic 842 requires lessees to recognize leases on balance sheet and disclose key information about leasing arrangements. Topic 842 establishes a ROU model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months.

Lease liability is initially measured at the present value of the sum of the remaining minimum rental payments and any amounts probable of being owed by the lessee under a residual value guarantee, discounted using incremental borrowing rate. Lease liability is subsequently re-measured at amortised cost using effective interest method.

ROU asset is initially measured at cost, which comprises the initial amount of lease liability adjusted for any prepaid or accrued rent, lease incentives, impairments (if applicable), or unamortized initial direct costs that would have qualified for capitalization under ASC Topic 842.

Lease cost is recognised on a straight-line basis over the term of the lease in the consolidated statement of income.

1.22 Debt issuance cost

Per FASB ASC 835-30, ASU No. 2015-03, the debt issuance cost related to recognized debt liability is presented in the balance sheet as a direct deduction from the debt liability consistent with the presentation of debt discount, thereby reducing the borrowing and increasing the effective interest rate.

1.23 New accounting standards

Recently issued accounting standards not yet adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this Update require that business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). For public business entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. The Group is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

2 Accounts receivable, net

Particulars	31-Mar-25	31-Mar-24
Accounts receivable	61,300,914	42,049,875
Less: Provision for doubtful debts	-	-
Total	61,300,914	42,049,875

The Group has availed invoice purchase facility from the bank which met the derecognition criteria since the Group had transferred substantially all the risks and rewards of ownership over such receivables as they are without recourse. Accordingly, as at 31 March 2025 is USD 24,690,594 (March 31, 2024 : USD 22,478,717 Million) has been derecognized from trade receivable.

3 Inventories

Particulars	31-Mar-25	31-Mar-24
Raw materials	16,679,688	14,719,054
Work in progress	1,322,622	1,633,809
Finished goods	54,910,800	38,364,239
Total	72,913,110	54,717,102

Based on the Group's assessment of slow-moving inventory and expiration policies, the Group is carrying a provision for its inventory of \$ 14,893,075 as of March 31, 2025 (March 31, 2024: \$11,639,055) for expired or near expiry products and damaged inventory.

The following table summarizes the inventory provision:

Particulars	31-Mar-25	31-Mar-24
Balance at the beginning of the year	11,639,055	17,300,338
Provision made during the year	9,109,829	7,239,656
Inventory consumed/utilised/written off during the year	(5,855,809)	(12,900,939)
Balance at the end of the year	14,893,075	11,639,055

4 Other current assets

Particulars	31-Mar-25	31-Mar-24
Prepaid expenses	2,074,083	2,109,634
Advance to vendors	631,543	1,180,329
Due from related parties	1,527,878	878,380
Advance income tax	3,081,688	1,622,060
Other receivables	13,232,219	6,859,632
Other assets	-	644,331
Total	20,547,411	13,294,366

5 Investments

Particulars	31-Mar-25	31-Mar-24
a) Investment at Cost - Securities of related parties:		
- 2,208,654 Common shares (March 31, 2024: 2,208,654) in Strides Pharma Global UK Limited, UK	1,589,385	1,589,385
- 212,709 Preference shares (March 31, 2024: 212,709) in Strides Pharma Global UK Limited, UK	32,567,876	32,567,876
b) Investment at Fair value - Other investments:		
- 260 Common shares (March 31, 2024: 2,076) in Sonnet Biotherapeutics Holdings Inc, USA*	346	3,861
Total	34,157,607	34,161,122

* On September 30, 2024, pursuant to requisite approval, there was reverse stock split in the ratio of 1 for 8 shares held of Sonnet Biotherapeutics Holding Inc.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

6 Property, plant and equipment, net

Particulars	31-Mar-25	31-Mar-24
Land	4,500,000	4,500,000
Buildings	18,052,798	18,003,302
Furniture and fixtures	154,801	149,285
Office equipment	173,240	165,137
Plant and machinery	9,599,818	9,122,888
Computers	314,402	288,733
Capital work-in-progress	3,552,177	775,048
Total property, plant and equipment, at cost	36,347,236	33,004,393
Accumulated depreciation	(7,827,886)	(5,677,361)
Property, plant and equipment, net	28,519,350	27,327,032

Depreciation expense for the year ended March 31, 2025 is \$ 2,150,525 (March 31, 2024: \$ 2,268,237).

7 Other intangible assets, net

Particulars	31-Mar-25	31-Mar-24
Gross other intangible assets	19,456,205	16,104,596
Accumulated amortization	(6,614,040)	(4,859,373)
Other intangible assets, net	12,842,165	11,245,223
Capital work-in-progress	600,000	-
Other intangible assets	13,442,165	11,245,223

Intangible assets amortization expense for the year ended March 31, 2025 is \$1,754,668 (March 31, 2024: \$1,196,372). The amortization expense for the next five years and thereafter is estimated as follows:

Year ending March 31:	Amount
2026	1,754,668
2027	1,754,668
2028	1,754,668
2029	1,754,668
2030	1,754,668
Thereafter	4,068,825
Total	12,842,165

Goodwill

Particulars	31-Mar-25	31-Mar-24
Balance at the beginning of the year	26,174,783	26,174,783
Movement during the year	-	-
Balance at the end of the year	26,174,783	26,174,783

The goodwill as referred in note 23 is on account of acquisition of 100% equity interest in Vensun Pharmaceuticals Inc., the business of which has been integrated with the primary business of the Company and accordingly the goodwill is allocated to a single reporting unit (Group)



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

8 Other non-current assets

Particulars	31-Mar-25	31-Mar-24
Capital advances	3,249,746	205,155
Prepaid expenses	61,017	-
Security deposits	628,372	934,597
Total	3,939,135	1,139,752

9 Accrued payables

Particulars	31-Mar-25	31-Mar-24
Accrued expenses	6,474,401	3,288,691
Accrued payroll	2,695,052	1,727,077
Interest accrued on borrowings	310,522	385,457
Advance from customer	95,911	-
Other statutory dues	330,019	272,069
Payable to related parties	69,309	230,182
Total	9,975,214	5,903,476

10 Debts

Particulars	31-Mar-25	31-Mar-24
Short-term debt	-	8,000,000
Current maturities of long-term debt	1,278,642	1,010,936
Long-term debt	50,397,080	45,551,932
Total	51,675,722	54,562,868

Details of security and terms of repayment for borrowings:

Particulars	31-Mar-25	31-Mar-24
(i) Bank loan 1	-	8,000,000
Gross loan sanctioned: 15,000,000		
Security: Corporate guarantee from Strides Pharma Science Limited, India, the Ultimate Parent Company		
Rate of interest: 6 months LIBOR + 250 bps p.a.		
Repayment terms: Repayable on demand		
(ii) Bank loan 2	49,041,563	44,097,909
Gross loan sanctioned: 95,000,000		
Security: First charge on the current assets and pari-passu first charge on the fixed assets of the Group		
Rate of interest: Daily Simple SOFR + 2.25% p.a.		
Repayment terms: : Repayable at the end of 5 years from the initial term		
(iii) Bank loan 3	1,767,582	2,778,518
Gross loan sanctioned: 5,000,000		
Security: First charge on the current assets and pari-passu first charge on the fixed assets of the Group		
Rate of interest: 3.62% p.a.		
Repayment terms: : Repayable in 60 equal monthly instalments. The outstanding term as at March 31, 2025 is 20 instalments.		
(iv) Bank loan 4	1,244,725	-
Gross loan sanctioned: 1,300,000		
Security: First charge on the current assets and pari-passu first charge on the fixed assets of the Group		
Rate of interest: 6.65% p.a.		
Repayment terms: : Repayable in 60 equal monthly instalments. The outstanding term as at March 31, 2025 is 57 instalments.		
Total	52,053,870	54,876,427

Reconciliation of debt:

Particulars	31-Mar-25	31-Mar-24
Short-term debt	-	8,000,000
Long-term debt	52,053,870	46,876,427
Gross debt	52,053,870	54,876,427
Less: Unamortised processing fee	(378,148)	(313,559)
Total debt, net of unamortised processing fee	51,675,722	54,562,868

The above loans are subject to certain financial covenants. As at March 31, 2025, the Group has complied with the prescribed covenants.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

11 Payable to related parties

The Group had entered into two loan facility agreements with Strides Pharma Limited, Cyprus ("SPL"), a related party, of upto \$8,000,000 and \$10,000,000. During the year ended March 31, 2018, SPL had merged into and now known as Strides Pharma International Limited, Cyprus. Subsequently, during the year ended March 31, 2019, the principal amount of this loan was repaid in full.

The line was unsecured and had an interest rate of 6% per annum.

The outstanding balance of \$3,136,618 (March 31, 2024: \$3,136,618) represents the accrued interest payable towards the above borrowings. The Group does not expect to settle this balance for a period of 12 months from the date of these financial statements and hence, the same has been disclosed under non-current liabilities.


12 Stockholder's equity

The Group had only one class of stock, i.e. Common stock. Par value of such stock outstanding is \$10 per share.

Common stock

The Group is authorized to issue 100,000 shares. As of March 31, 2025, 18,383 (March 31, 2024: 18,383) shares were issued and outstanding.

Stockholders are entitled to one vote for each common stock held by them. Upon liquidation as defined in the Company's amended and restated certificate of incorporation, the stockholders are entitled to receive all assets available for distribution to stockholders.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

13 Revenue from operations, net

Particulars	31-Mar-25	31-Mar-24
Sale of products and services	266,237,214	213,254,416
Total	266,237,214	213,254,416

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the year ended March 31, 2025 and March 31, 2024, respectively:

Particulars	31-Mar-25	31-Mar-24
Gross sales	564,764,234	478,741,623
Gross to net accruals / adjustments:		
Chargebacks	(235,641,075)	(230,623,395)
Rebates (including government rebate programs) and other sales allowances	(57,404,578)	(26,524,946)
Returns	(5,481,367)	(8,338,866)
Total gross to net adjustments	(298,527,020)	(265,487,207)
Net sales	266,237,214	213,254,416

Disaggregated revenue information

Particulars	31-Mar-25	31-Mar-24
1. Revenue disaggregated by product line:		
Sale of Pharmaceutical products	265,201,488	211,355,516
Service and licensing revenue	1,035,726	1,898,900
2. Revenue disaggregated by timing of recognition:		
At a point in time	266,237,214	213,254,416
3. Revenue disaggregated based on geographical regions:		
India	294,925	338,834
United States of America	265,942,289	212,915,582

14 Cost of revenue

Particulars	31-Mar-25	31-Mar-24
Cost of revenue	232,069,870	178,405,354
Total	232,069,870	178,405,354

15 Selling, general and administrative expenses

Particulars	31-Mar-25	31-Mar-24
Employee benefits expense	10,759,852	9,169,814
Marketing and business development expenses	357,484	225,573
Freight and warehousing expenses	9,508,666	7,930,742
Legal and professional expenses	12,116,536	9,566,926
Supply penalties	241,389	(61,189)
Insurance expenses	916,475	801,515
Operating lease expenses	2,013,691	2,823,100
Travelling expenses	539,757	386,763
Trade shows	74,791	182,515
Repairs and maintenance	4,946,903	5,022,802
Power and fuel	895,451	2,803,924
Rates and taxes	489,345	537,983
Others	2,637,735	4,228,122
Total	45,498,075	43,618,590

16 Other operating income

Particulars	31-Mar-25	31-Mar-24
Support service income	3,420,065	720,829
Capacity reservation fee (Refer note below)	24,825,000	21,000,000
Insurance claim	579,874	3,069,680
Total	28,824,939	24,790,509


Note

SPG reserved 75% of the Capacity of the Chestnut Ridge facility for \$ 24,825,000 (As on March 31, 2024: \$ 21,000,000) for manufacture and sale of products owned by SPG and manufactured by the company at the Chestnut Ridge plant. This income is disclosed under other operating income in the consolidated financial statements.

In lieu of reserving such capacity to manufacture the products at Chestnut Ridge Plant, the Group has paid to SPG the share of profit amounting to \$33,310,107 (As on March 31, 2024: \$26,318,603). This is included in the Cost of revenue in the consolidated financial statements.

17 Other (income) / expense

Particulars	31-Mar-25	31-Mar-24
Fair value loss on investments	3,515	12,581
Miscellaneous income	(29,647)	(18,184)
Total	(26,132)	(5,603)



Strides Pharma Inc.**Notes forming part of the consolidated financial statements***(All amounts in \$, except share and per share data)***18 Income taxes**

The federal and state income tax provision for the year is \$2,772,096 (March 31, 2024 : \$ 266,426) (after set-off of the US tax loss carry forwards from prior years against the taxable income of the year ended March 31, 2024). Accordingly, the current Income tax expense for the year ended March 31, 2025 is \$2,772,096 (March 31, 2024: \$266,426).

Deferred tax expense / (benefit) recorded for the year is (\$981,951) (March 2024: \$1,148,926) at federal and state level.

ETR for the FY 24-25 is 21.77% as against the statutory rate of 23.76% (including Federal and state tax) (*Statutory ETR would vary year on year basis the state income apportionment).

For the year ended March 31, 2025, the provision for income taxes differed from the statutory tax rate primarily due to state income taxes, true-ups and various non deductible items.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Group's deferred income tax assets and liabilities as of March 31, 2025 are as follows:

Particulars	31-Mar-25	31-Mar-24
Deferred tax assets:		
Accrued expenses	499,806	317,069
Investments	-	2,810
Net operating loss carry forward	1,161,239	1,338,460
Inventory obsolescence reserve	3,518,530	2,765,375
Interest related adjustments	1,983,984	2,314,194
Research and development	999,180	1,128,363
Others	270,079	243,914
	8,432,818	8,110,185
Valuation allowance	-	-
Total deferred tax assets	8,432,818	8,110,185
Deferred tax liabilities:		
Property, plant and equipment	(1,062,393)	(1,365,242)
Other intangible assets	(2,156,803)	(2,489,547)
Unrealised gain on investments	(88)	(917)
Others	-	(22,896)
Total deferred tax liabilities	(3,219,284)	(3,878,602)
Deferred tax assets (net)	5,213,534	4,231,583


The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management consider it to be more likely that all of the deferred tax assets will be realized and hence no valuation allowance on the net operating loss carry forwards is created.

The Group files a consolidated tax return for Strides Pharma Inc. and Vensun Pharmaceuticals Inc. As of March 31, 2025, the Group has State net operating loss carry forwards aggregate of which may not exceed respectively \$10,757,516, for offset against future taxable income.

The federal losses are subject to Sections 382 and 383 of the Internal Revenue Code. The Group has completed a Section 382 study and determined the annual limitation resulting from any prior ownership changes. Accordingly, the timing or amount of federal net operating loss carry forwards available for utilization in the future will be limited in any given year and the expected amount of federal NOL projected to be utilized in the future may not exceed an amount of \$3,945,720.

Further, the Group does not have any unrecognised tax benefits as of March 31 2025 and 2024. There are open statutes of limitations for taxing authorities to audit the Group's tax returns from 2017 through current period.



Strides Pharma Inc.
Notes forming part of the consolidated financial statements
(All amounts in \$, except share and per share data)

19 Leases

The Group facilitates an office space and factory space under operating lease.

Leases that contain non-lease components are accounted for as a single component and recorded on the balance sheet for certain asset classes including equipment. Non-lease components include, but are not limited to, common area maintenance and service arrangements.

The table below presents the classification of the operating lease and finance lease assets and liabilities:

Leases	Balance sheet classification	31-Mar-25	31-Mar-24
Assets			
Operating lease right of use assets	Non-current assets	3,347,841	4,435,053
Liabilities			
Operating lease liabilities	Non-current liabilities	2,401,758	3,253,733
	Current liabilities	1,126,960	1,223,293
Total Operating lease liabilities		3,528,718	4,477,026

Operating lease expense has been recognized in the consolidated statements of income under the head "Selling, general & administrative expenses"

The following table contains supplemental cash flow information related to leases for the years ended March 31, 2025 and March 31, 2024:

	31-Mar-25	31-Mar-24
Cash paid for amounts included in the measurement of lease liabilities:		
Cash flow from operating leases	1,268,818	2,804,665

The Group facilitates an office space and factory premises under operating leases which have non-cancellable terms through August 2028.

Future minimum payments under non-cancellable operating lease are as follows:

Year ended March 31,	Amount
2026	1,171,809
2027	1,206,947
2028	1,243,139
2029	418,442
2030 and onwards	-
Total minimum lease payments	4,040,337
Less: imputed interest	511,619
Operating lease liabilities	3,528,718

Particulars	31-Mar-25	31-Mar-24
Weighted average remaining lease terms (years) – operating leases	3.34	4.42
Weighted average – discount rate	8.00%	8.00%




20 Related party transactions and balances

The following table identifies the Strides Group's related parties with whom it has entered into transactions:

Related party transactions

Sl. No.		Ultimate Holding Company		Holding Company		Fellow subsidiary		Fellow associate		Enterprises owned or significantly influenced by KMP and relative of KMP	
		31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24
Purchase of goods											
1	Strides Pharma Science Limited, India	663,693	326,631	-	-	-	-	-	-	-	-
2	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	143,940,281	128,774,255	-	-	-	-
3	Tenshi Kaizen Private Limited, India	-	-	-	-	3,796,141	-	-	-	-	71,257
4	Strides Pharma International AG (formerly Fairmed Healthcare AG) Switzerland	-	-	-	-	-	-	-	-	-	-
5	Strides Softjets Pte Ltd., Singapore	-	-	-	-	-	-	-	-	39,852,666	-
6	Sterisience Pte Ltd, Singapore	-	-	-	-	-	-	-	-	10,051,905	5,606,866
Services received											
1	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	-	68,251	-	-	-	-
2	Strides Pharma Canada Inc, Canada	-	-	-	-	533,270	274,145	-	-	-	-
3	Arco Lab Private Limited, India	-	-	-	-	199,806	150,559	-	-	-	-
4	Strides Pharma Science Limited, India	785,492	992,933	-	-	-	-	-	-	-	-
5	White Crow Research Private Limited, India	-	-	-	-	-	-	-	-	-	-
Guarantee commission											
1	Strides Pharma Science Limited, India	23,878	80,221	-	-	-	-	-	-	-	-
Support service income											
1	Onesource Specialty Pharma Limited (Formerly known as Stelis Biopharma Limited) *	187,915	-	-	-	-	-	309,568	-	66,094	-
2	Strides Pharma Science Limited, India	-	-	-	-	-	-	-	-	-	-
3	Sterisience Pte Ltd, Singapore	-	-	-	-	-	-	-	-	684,763	425,858
4	Arco Lab Private Limited, India	-	-	-	-	8,434	-	-	-	-	-
5	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	2,572,166	-	-	-	-	-
6	Strides Consumer LLC, USA	-	-	-	-	59,404	-	-	-	-	-
Purchase of Asset											
1	Onesource Specialty Pharma Limited (Formerly known as Stelis Biopharma Limited) *	-	-	-	-	-	-	-	-	600,000	-
Sale of goods											
1	Strides Pharma Science Limited, India	294,925	318,834	-	-	-	-	-	-	-	-
Capacity Reservation fees											
1	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	24,825,000	21,000,000	-	-	-	-
Expenses incurred on behalf of / (incurred by), net											
1	Strides Pharma Science Limited, India	55,312	(231,635)	-	-	1,533,216	380,000	-	-	-	-
2	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	(8,509)	3,550	-	-	-	-
3	Strides Pharma Canada Inc, Canada	-	-	-	-	6,092	-	-	-	-	-
4	Strides Consumer LLC, USA	-	-	(6,000)	(7,500)	-	-	-	-	138	-
5	Strides Arcolab International Limited, UK	-	-	-	-	-	-	-	-	-	-
6	Onesource Specialty Pharma Limited (Formerly known as Stelis Biopharma Limited)*	-	-	-	-	-	-	-	-	5,538	-
7	Nuari Pharma Private Limited, India	-	-	-	-	-	-	-	-	-	8,900
8	Sterisience Pte Ltd, Singapore	-	-	-	-	-	-	-	-	-	1,435
9	Tenshi Kaizen Private Limited	-	-	-	-	-	-	-	-	-	-
10	Bellapharm S.p.A, Italy	-	-	-	-	22,777	17,435	-	-	-	(84,000)



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)



20 Related party transactions and balances

Related party balances

Sl. No.	Name	Ultimate Holding Company		Holding Company		Fellow subsidiary		Associate of Ultimate Parent		Enterprises owned or significantly influenced by KMP and relative of KMP	
		31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24
Trade payables											
1	Strides Pharma Science Limited, India	240,537	924,630	-	-	-	-	-	-	-	-
2	Strides Pharma Global Pte Limited, Singapore	-	-	-	-	65,460,407	36,421,002	-	-	-	-
3	Tenshi Kaizen Private Limited	-	-	-	-	-	-	-	-	-	3,511
4	Sterisience Pte Ltd	-	-	-	-	-	-	-	-	1,359,763	1,462,956
5	Onsource Specialty Pharma Limited (Formerly known as Stelis Biopharma Limited) *	-	-	-	-	-	-	-	-	599,862	-
6	Strides Pharma International AG (Formerly Fairmed Healthcare AG)	-	-	-	-	3,796,141	-	-	-	-	-
7	Strides Softgels Pte Ltd #	-	-	-	-	-	-	-	-	9,160,859	-
8	White Crow Research Private Limited, India	-	-	-	-	-	-	-	-	-	(11,000)
Other receivables/(payables)											
1	Arco Lab Private Limited, India	-	-	-	-	(41,424)	(34,000)	-	-	-	-
2	Bellapharm S p A Italy	-	-	-	-	40,212	17,435	-	-	-	-
3	Naari Pharma Private Limited India	-	-	-	-	-	-	-	-	138	2,410
4	Shasun USA Inc, USA	-	-	-	-	-	-	-	-	166,048	166,048
5	Strides Consumer LLC, USA	-	-	-	-	793,800	-	-	-	-	-
6	Strides Pharma Science Limited, India	6,034	(109,341)	-	-	-	-	-	-	-	-
7	Onsource Specialty Pharma Limited (Formerly known as Stelis Biopharma Limited) *	-	-	-	-	-	-	-	373,558	66,098	-
8	Strides Arcolab International Limited, UK	-	-	(1,500)	-	-	-	-	-	-	-
9	Strides Pharma Global (UK) Limited, UK	-	-	-	-	(26,386)	(26,513)	-	-	-	-
10	Solara Active Pharma Science Limited, India	-	-	-	-	-	-	-	-	18,840	18,840
11	Tenshi Kaizen Private Limited, India	-	-	-	-	-	-	-	-	2,977	2,977
12	Alima Innovations Inc., USA	-	-	-	-	-	(6,548)	-	-	-	-
13	Strides Pharma Canada Inc, Canada	-	-	-	-	394,846	258,421	-	-	-	-
14	Sterisience Pte Ltd	-	-	-	-	-	-	-	-	41,877	38,680
Interest payable											
1	Strides Pharma International Limited, Cyprus	-	-	-	-	3,136,618	3,136,618	-	-	-	-
Investments											
1	Strides Pharma Global UK Limited, UK	-	-	-	-	34,157,261	34,157,261	-	-	-	-

The Ultimate Parent entity has received the order approving the Scheme of demerger of CDMO and Soft Gelatin Business on November 14, 2024 from the regulator with appointed date of April 1, 2024. Pursuant to the Demerger, Strides Softgels Pte Ltd ceased to be subsidiary effective from 01 April 2024.

* The Ultimate Parent entity has received the order approving the Scheme of demerger of CDMO and Soft Gelatin Business on November 14, 2024 from the regulator, with appointed date of April 1, 2024. Pursuant to the Demerger, Onsource Specialty Pharma Limited ceased to be associate effective from 01 April 2024.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

- 21 On March 31, 2020, US Food and Drug Administration (USFDA or the Agency) issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription (Rx) and over-the-counter (OTC) Ranitidine drugs from the market immediately. This step was based on their ongoing investigation of the N-Nitrosodimethylamine (NDMA) impurity in Ranitidine medications. As a result, effective April 01, 2020, the Group has ceased further distribution of the product and is currently in the process of withdrawing the product from the market.

During the year ended March 31, 2022, USFDA issued a letter to the Group to test for the presence of Azide impurity(s) in Losartan. The Azide impurity(s) are API process impurity(s), with the API manufacturer also receiving a similar letter from USFDA. The results confirmed the presence of Azide impurity(s) in the batches tested. As a result, the group proposed to initiate a voluntary recall of specific batches which had the Azide impurity(s).



During the current year ended March 31, 2025 and previous year ended March 31, 2024, with respect to the above mentioned recalls, the Group is carrying sufficient provision for sales return and has recorded an amount of USD 3.51 million and USD 3.50 million respectively, towards other expenses related to its product withdrawal and settlements. Furthermore, the expenses recorded also include legal fees incurred by the Group in respect of its ongoing litigations with respect to these recalled products. These amounts, in line with earlier periods, have been recorded as an expense within Selling, general and administrative expenses in the consolidated statement of income during the period.

- 22 During the year ended March 31, 2025, the Group voluntarily initiated recall of testosterone due to the presence of trace amounts of Benzene and the Group is reformulating the Product to ensure conformance with the FDA's updated requirements. Subsequent to the year end, the Group has received certain complaints which are legal in nature and are under evaluation. Accordingly the Group has created a provision of \$ 1,500,000 towards the recall and other related expense which has been presented in Selling, general and administrative expenses in the consolidated statement of income during the period.

23 Business combinations

Vensun Pharmaceuticals Inc., USA ("Vensun")

On January 30, 2019, the Company had acquired 100% of equity interest in Vensun Pharmaceuticals Inc., USA ("Vensun"), a US-based generics company, for a consideration of \$6,560,859 in cash and balance contingent on future revenues. The contingent consideration was fair valued based on the probability weighted estimated future cash outflows. The fair value of contingent consideration remaining payable at March 31, 2024 is \$ 678,341. Further, during the current year subsequent to the expiry of the agreement tenure the entire balance amounting to \$678,341 was written back to the consolidated statement of Income.



Strides Pharma Inc.

Notes forming part of the consolidated financial statements

(All amounts in \$, except share and per share data)

24 Commitments and contingencies

a) Commitments

Particulars	31-Mar-25	31-Mar-24
Capital commitments, net of advances	1,423,247	2,128,054

b) Contingencies

The Group is involved in various litigations including commercial matters that arise from time to time in the ordinary course of business. Management is of the view that these litigations are in preliminary stages and the resolution of these matters will not have any material adverse effect on the Group's financial position or results of operations.

The Group remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the Group's operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the Group may be exposed to significant litigation concerning the scope of our and others' rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.

25 Financial instruments

(i) Concentration of credit risk

Financial instruments which potentially subject the Group to concentrations of credit risk consist principally of accounts receivable. The Group generated approximately 57% (March 31, 2024: 58%) of net revenues from four customers during the year ended March 31, 2025.

The table below breaks down the percentage of revenue related to the four customers:

Customers	March 31, 2025	March 31, 2024
Customer A	15%	17%
Customer B	18%	15%
Customer C	11%	13%
Customer D	13%	13%

Global economic conditions, governmental actions and customer-specific factors may require re-evaluation of the collectability of the receivables and could potentially incur additional credit losses.

The Group's largest vendor is Strides Pharma Global Pte Limited, Singapore. Also, major products sold by the Group are manufactured in India.

(ii) Foreign currency and interest rate management

The Group operates on a global basis and is exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The hedging policy attempts to manage these risks to an acceptable level based on management's judgment of the appropriate trade-off between risk, opportunity and costs.

Group's policy is to manage interest costs using the mix of fixed- and floating-rate debt that management believe is appropriate at that time.

The Group is not significantly exposed to foreign exchange risk as majority of its transactions are held in USD, its functional currency.

The Group does not hold any instruments for trading purposes and none of its outstanding derivative instruments contain credit-risk-related contingent features.



Strides Pharma Inc.**Notes forming part of the consolidated financial statements***(All amounts in \$, except share and per share data)***26 Fair value measurements**

The Group uses valuation approach that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels in accordance with ASU 2011-04:

Level 1 Inputs: Quoted prices in active markets that we have the ability to access for identical assets or liabilities;

Level 2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuations in which all significant inputs are observable in the market; and

Level 3 Inputs: Valuations using significant inputs that are unobservable in the market and include the use of judgment by management about the assumptions market participants would use in pricing the asset or liability.

The Group's financial instruments consist of accounts receivables, cash and cash equivalents, investments, current assets, accounts payables and borrowings. The estimated fair value of cash, other current assets, and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. None of these instruments are held for trading purposes.

The Group measures investments, other than investments, at fair value on a recurring basis. The fair value measurements of these investments were determined using the following inputs as of March 31, 2025 and March 31, 2024:

Particulars	Basis of fair valuation measurement	31-Mar-25	31-Mar-24
Assets			
Investment in common stock of Sonnet Biotherapeutics Holdings Inc, USA	Level 1 inputs - Quoted price of investment in active markets	346	3,861
Total		346	3,861
Liabilities			
Contingent payment related to acquisitions	Level 3 inputs - Significant unobservable inputs	-	678,341
Total		-	678,341

For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs.

Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques. The fair value of milestone payments reflects management's expectations of probability of payment, and increases as the probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated.

The following table is a reconciliation of our recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions.

Particulars	31-Mar-25	31-Mar-24
Fair value at the beginning of the year	678,341	1,319,050
Add: Unwinding impact/ Fair valuation of contingent consideration payable	(678,341)	(640,709)
Less: Payments during the year	-	-
Fair value at the end of the year	-	678,341

27 Subsequent events

The Group has evaluated subsequent events occurring after the consolidated financial statements date through June 28, 2025 which is the date the consolidated financial statements were available to be issued. Based on the evaluation, the Group has no subsequent events that requires any adjustment to the consolidated financial statements and /or disclosure.

